These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17078187)

  • 21. Adults with diabetes - pharmacological management of hypertension.
    Jackowski L; Crockett J; Rowett D
    Aust Fam Physician; 2008 Jun; 37(6):419-21. PubMed ID: 18523694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
    Chi YW; Jaff MR
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):475-89. PubMed ID: 18307227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of exercise training in peripheral arterial disease.
    Milani RV; Lavie CJ
    Vasc Med; 2007 Nov; 12(4):351-8. PubMed ID: 18048473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral arterial disease: a review of disease awareness and management.
    Watson K; Watson BD; Pater KS
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):365-79. PubMed ID: 17296541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of beta-blockers on peripheral skin microcirculation in hypertension and peripheral vascular disease.
    Ubbink DT; Verhaar EE; Lie HK; Legemate DA
    J Vasc Surg; 2003 Sep; 38(3):535-40. PubMed ID: 12947273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antihypertensive therapy in patients with hypertension and intermittent claudication.
    Svendsen TL; Tønnesen KH
    Dan Med Bull; 1987 Dec; 34 Suppl 1():10-1. PubMed ID: 3436164
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cardiovascular prevention with peripheral artery disease].
    Vértes A
    Orv Hetil; 2007 Jul; 148(28):1303-9. PubMed ID: 17611180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected.
    Paraskevas KI; Giannoukas AD; Mikhailidis DP
    Ann Vasc Surg; 2009; 23(5):690-9. PubMed ID: 19747617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of (a)symptomatic peripheral arterial disease; the additional value of ankle-brachial index on cardiovascular risk stratification.
    van Kuijk JP; Flu WJ; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2009 Sep; 38(3):312-3. PubMed ID: 19524459
    [No Abstract]   [Full Text] [Related]  

  • 32. Underestimating the hazards of peripheral artery disease.
    Harv Heart Lett; 2004 Jan; 14(5):7. PubMed ID: 14734296
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiology patient page. Peripheral arterial disease.
    Gornik HL; Beckman JA
    Circulation; 2005 Apr; 111(13):e169-72. PubMed ID: 15811861
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease.
    Sigvant B; Wiberg-Hedman K; Bergqvist D; Rolandsson O; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):39-46. PubMed ID: 19237996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAD. The "vascular" in cardiovascular disease.
    Braunstein JB
    Diabetes Forecast; 2002 Sep; 55(9):46-8. PubMed ID: 14765463
    [No Abstract]   [Full Text] [Related]  

  • 36. When hypertension and diabetes coexist: strategies for cardiorenal protection.
    Weber MA
    Postgrad Med; 2000 Oct; 108(5 Suppl):12-8. PubMed ID: 19667536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are elderly people with the HOPE criteria prescribed angiotensin-converting enzyme inhibitors?
    Sumukadas D; Witham MD; Struthers AD; McMurdo ME
    J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):26. PubMed ID: 15136970
    [No Abstract]   [Full Text] [Related]  

  • 38. Inter-society consensus for the management of peripheral arterial disease.
    Norgren L; Hiatt WR; Dormandy JA; Nehler MR; Harris KA; Fowkes FG; Rutherford RB;
    Int Angiol; 2007 Jun; 26(2):81-157. PubMed ID: 17489079
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
    Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
    J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.